Education for you.

Novo Nordisk provides professional educational materials to help you make an informed treatment decision. You can download materials, share them with colleagues, or order for delivery to your office.

  • Professional Brochure

    This brochure will help you understand the needs and challenges patients face as they transition through key life milestones.

  • Counsel the Switch

    This tool can help you educate patients about Novoeight®, with information about the product attributes, and guidance for addressing concerns.

  • Patient Stories

    Team Novo8™ is a group of patients who switched to Novoeight® and spend their time helping others with hemophilia A. Hear more about their mission, and how your patients can benefit from their experiences.

Education for your patients.

Help your patients learn about hemophilia, with educational materials available through your Novo Nordisk representative, or to download and share.

 Novoeight® brochure

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

Please click here for Prescribing Information.